Robert Burakoff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Robert Burakoff has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Natan Feldman
9 shared publications- Walter Wai-Yip Chan
Division of Gastroenterology, Hepatology and Endoscopy Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA
8 shared publications - Wai-Kit Lo
Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital , Boston, MA
7 shared publications Hilary J. Goldberg
4 shared publications- Edward L. Barnes
Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC
2 shared publications Frederick L. Makrauer
2 shared publications
Latest Publications
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S658-S659
Low Nocturnal Baseline Impedance is Prevalent and a Promising Marker for Reflux During Pre-Lung Transplant Evaluation
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S658-S659
Low Nocturnal Baseline Impedance is Prevalent and a Promising Marker for Reflux During Pre-Lung Transplant Evaluation
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S5-S6
Increased Acid Exposure on Pre-Transplant Reflux Testing Independently Predicts Significant Pulmonary Function Decline after Lung Transplantation
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S5-S6
Increased Acid Exposure on Pre-Transplant Reflux Testing Independently Predicts Significant Pulmonary Function Decline after Lung Transplantation
- Open Access
- 1 December 2016
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 22 (12) , 2956-2965
New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes
Despite advances in our understanding of the pathophysiology underlying inflammatory bowel disease, there remains a significant need for biomarkers th
- 1 December 2016
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 22 (12) , 2956-2965
Open AccessNew Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes
Despite advances in our understanding of the pathophysiology underlying inflammatory bowel disease, there remains a significant need for biomarkers th
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S271-S272
Sa1293 Increased Acid Exposure on Pre-Transplant Reflux Testing is Associated with Chronic Rejection after Lung Transplantation
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S271-S272
Sa1293 Increased Acid Exposure on Pre-Transplant Reflux Testing is Associated with Chronic Rejection after Lung Transplantation
- 19 October 2014
- Published by Springer Nature
- p. 251-254
Treatment of Ulcerative Proctitis
- 1 August 2013
- Vol. 9 (8) , 543-4
Review.
- Open Access
- 23 July 2013
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 32 (1) , 44
Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study
Background: Colonoscopy is widely regarded to be the gold standard for colorectal cancer (CRC) detection. Recent studies, however, suggest that the effectiveness of colonoscopy is mostly confined to tumors on the left side of the colon (descending, sigmoid, rectum), and that the technology has poor tumor detection for right-sided (cecum, ascending, transverse) lesions. A minimally invasive test that can detect both left-sided and right-sided lesions could increase the effectiveness of screening colonoscopy by revealing the potential presence of neoplasms in the right-sided “blind spot”. Methods: We previously reported on a seven-gene, blood-based biomarker panel that effectively stratifies a patient’s risk of having CRC. For the current study, we assessed the effectiveness of the seven-gene panel for the detection of left- and right-sided CRC lesions. Results were evaluated for 314 patients with CRC (left-sided: TNM I, 65; TNM II, 57; TNM III, 60; TNM IV, 17; unknown, 9. right-sided: TNM I, 28; TNM II, 29; TNM III, 38; TNM IV, 12; unknown, 1 and including two samples with both left and right lesions) and 328 control samples. Blood samples were obtained prior to clinical staging and therapy. Most CRC subjects had localized disease (stages I and II, 58%); regional (stage III) and systemic (stage IV) disease represented 32% and 9%, respectively, of the study population. Results: The panel detected left-sided (74%, 154/208) and right-sided (85%, 92/108) lesions with an overall sensitivity of 78% (215/316) at a specificity of 66% (215/328). Treatable cancer (stages I to III) was detected with left-sided lesion sensitivity of 76% (138/182) and right-sided sensitivity of 84% (80/95). Conclusion: This seven-gene biomarker panel detected right-sided CRC lesions across all cancer stages with a sensitivity that is at least equal to that for left-sided lesions. This study supports the use of this panel as the basis for a patient-friendly, blood-based test that can be easily incorporated into a routine physical examination in advance of colonoscopy to provide a convenient companion diagnostic and a pre-screening alert, ultimately leading to enhanced CRC screening effectiveness.
- 23 July 2013
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 32 (1) , 44
Open AccessBlood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study
Background: Colonoscopy is widely regarded to be the gold standard for colorectal cancer (CRC) detection. Recent studies, however, suggest that the effectiveness of colonoscopy is mostly confined to tumors on the left side of the colon (descending, sigmoid, rectum), and that the technology has poor tumor detection for right-sided (cecum, ascending, transverse) lesions. A minimally invasive test that can detect both left-sided and right-sided lesions could increase the effectiveness of screening colonoscopy by revealing the potential presence of neoplasms in the right-sided “blind spot”. Methods: We previously reported on a seven-gene, blood-based biomarker panel that effectively stratifies a patient’s risk of having CRC. For the current study, we assessed the effectiveness of the seven-gene panel for the detection of left- and right-sided CRC lesions. Results were evaluated for 314 patients with CRC (left-sided: TNM I, 65; TNM II, 57; TNM III, 60; TNM IV, 17; unknown, 9. right-sided: TNM I, 28; TNM II, 29; TNM III, 38; TNM IV, 12; unknown, 1 and including two samples with both left and right lesions) and 328 control samples. Blood samples were obtained prior to clinical staging and therapy. Most CRC subjects had localized disease (stages I and II, 58%); regional (stage III) and systemic (stage IV) disease represented 32% and 9%, respectively, of the study population. Results: The panel detected left-sided (74%, 154/208) and right-sided (85%, 92/108) lesions with an overall sensitivity of 78% (215/316) at a specificity of 66% (215/328). Treatable cancer (stages I to III) was detected with left-sided lesion sensitivity of 76% (138/182) and right-sided sensitivity of 84% (80/95). Conclusion: This seven-gene biomarker panel detected right-sided CRC lesions across all cancer stages with a sensitivity that is at least equal to that for left-sided lesions. This study supports the use of this panel as the basis for a patient-friendly, blood-based test that can be easily incorporated into a routine physical examination in advance of colonoscopy to provide a convenient companion diagnostic and a pre-screening alert, ultimately leading to enhanced CRC screening effectiveness.